跳至主要内容
临床试验/NCT01174992
NCT01174992
已完成
2 期

A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair

Ethicon, Inc.12 个研究点 分布在 6 个国家目标入组 139 人2010年7月
适应症Dura Defects

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
Dura Defects
发起方
Ethicon, Inc.
入组人数
139
试验地点
12
主要终点
Proportion of success
状态
已完成
最后更新
13年前

概览

简要总结

The objective of this study is to evaluate the safety and efficacy of EVICEL for use as an adjunct to dura sutures in elective cranial surgery to provide intraoperative watertight closure.

详细描述

This is a randomized, multi-center controlled study evaluating the effectiveness of EVICEL\* as an adjunct to sutured dural closure compared to control to obtain an intraoperative watertight dural closure.

注册库
clinicaltrials.gov
开始日期
2010年7月
结束日期
2011年10月
最后更新
13年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
Ethicon, Inc.
责任方
Sponsor

入排标准

入选标准

  • Patient undergoing elective craniotomy/craniectomy
  • Age greater than or equal to 18 years
  • Patients who are able and willing to comply with the procedures required by the protocol.
  • Signed and dated written informed consent from the subject or from his/her legal representative prior to any study-related procedures.

排除标准

  • Chemotherapy or radiation therapy within 7 days following surgery.
  • Conditions compromising the immune system.
  • Known hypersensitivity to the components (human fibrinogen, arginine hydrochloride, glycine, sodium chloride, sodium citrate, calcium chloride, human thrombin, human albumin, mannitol and sodium acetate) of the investigational product.
  • Female subjects of childbearing potential with a positive pregnancy test prior to surgery.
  • Female subjects who are breastfeeding or intend to become pregnant during the clinical study period.
  • Participation in another clinical trial with exposure to another investigational drug or device within 30 days prior to enrollment.
  • Major intraoperative findings or complications identified by the surgeon that may preclude conduct of the planned surgical procedure.

结局指标

主要结局

Proportion of success

时间窗: Day 1 (intraoperative)

Proportion of success (intraoperative watertight closure) in the treatment of intraoperative CSF leakage.

次要结局

  • Incidence of CSF leakage(Day 30 post-op)
  • Incidence of adverse events(up to 30 days post-op)
  • Incidence of surgical site infections(Day 5 and 30 post-op)

研究点 (12)

Loading locations...

相似试验